Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Aiming to Create an Inclusive Society
[PDF 95KB]
Donation to Organizations Committed to Fostering Para-Sports -
Launch of the Immunosuppressant
[PDF 172KB]
“CellCept® Powder for Oral Suspension 31.8%” -
Chugai’s ALK Inhibitor “Alecensa®”
[PDF 173KB]
Accelerated Approval in Three Months after Priority Review Designation in the US -
Launch of the ALK Inhibitor “Alecensa® Capsule 150mg”
[PDF 149KB]
-Making Contribution to the Improvement of Convenience of Patients- -
Organizational and Personnel Changes
[PDF 214KB] -
Anti-Cancer Agent “Xeloda®,”
[PDF 172KB]
Obtained Approval for Additional Indication of
“Postoperative Adjuvant Chemotherapy for Gastric Cancer” -
Anti-Cancer Agent “Avastin®,”
[PDF 126KB]
Judgment of the Supreme Court regarding Patent Term Extension -
Selective SGLT2 Inhibitor “DEBERZA®” Enters a New Phase
[PDF 153KB] -
Chugai to Newly Construct an Antibody API Manufacturing Plant
[PDF 215KB]
Capable of High-Mix Low-Volume Production
in Preparation for the Consecutive Launch of Innovative Projects -
F. Hoffmann-La Roche Announces Third Quarter Sales 2015
[PDF 79KB] -
Personnel Changes
[PDF 111KB] -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 148KB] -
NICE Recommends Chugai’s RoACTEMRA® (tocilizumab) as Monotherapy for Treatment of Severe Rheumatoid Arthritis
[PDF 117KB] -
Disclosure of Information on Chugai’s 2014 Corporate Activities
[PDF 111KB]
Based on Transparency Guidelines -
Anti-Cancer Agent “Avastin®,”
[PDF 86KB]
Application for Approval of Additional Indication of Recurrent/Advanced Cervical Cancer -
Chugai Selected for the Second Consecutive Year for the Dow Jones Sustainability Asia Pacific Index,
[PDF 98KB]
an Index for Socially Responsible Investment -
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®)
[PDF 211KB]
in the UK by Chugai Pharma UK Ltd. -
Chugai’s ALK Inhibitor “Alectinib,” New Drug Application
[PDF 136KB]
Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer
in the United States -
Chugai’s Bispecific Antibody “ACE910” for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
[PDF 166KB] -
Filing of Public Knowledge-Based Application for Immunosuppressant “CellCept®” for
[PDF 149KB]
Additional Indication of Lupus Nephritis -
Supplemental Approval of New Formulation of Immunosuppressant,
[PDF 186KB]
“CellCept® Powder for Oral Suspension 31.8%” -
Organizational and Personnel Changes
[PDF 146KB] -
Relocation of the Tokyo First Branch
[PDF 119KB] -
F. Hoffmann-La Roche Announces Half Year Results 2015
[PDF 102KB] -
Licensing Agreement for Agent Targeting Prevention of Recurrence of Hepatocellular Carcinoma “Peretinoin”
[PDF 123KB] -
Integration and Reorganization of Overseas Subsidiaries
[PDF 247KB]
Aiming to Further Accelerate Overseas Business Activities -
Positive Interim Data from Phase I/II study of Chugai’s Bispecific Antibody "ACE910" Presented at the ISTH 2015 Congress
[PDF 176KB] -
Japanese Study for ACTEMRA® Showed New Data on the
[PDF 121KB]
Improvement of Symptoms and Safety in Rheumatoid Arthritis at
EULAR 2015 -
Guidebook for Employees
[PDF 452KB]
“Working Support Handbook for Cancer Patients” -
Filing of New Drug Application for M8010, a Topical Preparation
[PDF 121KB]
Combining an Active Vitamin D3 Derivative and a Corticosteroid -
Determination of Terms and Conditions of Stock Options
[PDF 110KB]
(Stock Acquisition Rights) -
Relief Efforts Support for the Disaster Area Struck by the Earthquake in Nepal
[PDF 109KB] -
“Team Chugai” to Take Part in “Relay for Life Japan”
[PDF 2.0MB] -
Amendment of Basic Policies Concerning Internal Controls
[PDF 147KB] -
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 115KB] -
F. Hoffmann-La Roche Announces First Quarter Sales 2015
[PDF 83KB] -
Transfer of Marketing Rights for Mercazole® and Propacil®
[PDF 108KB]
from Chugai Pharmaceutical to Aska Pharmaceutical -
Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate
[PDF 109KB]
Oral Formulation, Bisphosphonate Antiresorptive Agent,
in Japanese Patients with Osteoporosis Presented -
Incident Report on Missing Deleterious Substance
[PDF 151KB] -
Approval of Antiviral Drug, Copegus® for Additional Indication
[PDF 152KB]
-First All-Oral Treatment Regimen for Patients with Serogroup 2 HCV in Japan- -
Chugai selected as a “Nadeshiko Brand,” a company that is
[PDF 162KB]
exceptional in promoting the success of women in the workplace
— Active diversity measures evaluated by outside agencies — -
90th Anniversary Commemorative Projects
[PDF 196KB]
Aim at Contributing to Development of Local Communities and
Medical/Pharmaceutical Sciences -
Renewal of “Cancer Information Guide,” a Website for Patients
[PDF 117KB] -
Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem® Cell Therapy for Ischemic Stroke in Japan
[PDF 140KB] -
Launch of the Anti-Cancer Agent / BRAF Inhibitor “Zelboraf®”
[PDF 134KB] -
New Drug Application Filed for Ibandronate Sodium Hydrate Oral Agent, Bisphosphonate Antiresorptive Agent
[PDF 94KB] -
Chugai Won the Second Prize
[PDF 163KB]
in the 17th NIKKEI Annual Report Awards -
Chugai to Establish the Organization
[PDF 123KB]
Specializing in Early Clinical Development -
Personnel Changes
[PDF 123KB] -
Notice of Distribution of Retained Earnings
[PDF 96KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2014
[PDF 150KB]